Ameritas Investment Partners buys $7.1 Million stake in Amgen (AMGN)

Amgen (AMGN) : Ameritas Investment Partners scooped up 5,103 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 46,643 shares of Amgen which is valued at $7.1 Million.Amgen makes up approximately 0.49% of Ameritas Investment Partners’s portfolio.

Other Hedge Funds, Including , Opus Investment Management Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 3,100 additional shares and now holds a total of 33,600 shares of Amgen which is valued at $5.1 Million. Amgen makes up approx 0.98% of Opus Investment Management Inc’s portfolio.Manufacturers Life Insurance Company The boosted its stake in AMGN in the latest quarter, The investment management firm added 66,607 additional shares and now holds a total of 3,433,014 shares of Amgen which is valued at $523 Million. Amgen makes up approx 0.82% of Manufacturers Life Insurance Company The’s portfolio. Archford Capital Strategies sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 19 shares of AMGN which is valued $2,895.Tortoise Investment Management reduced its stake in AMGN by selling 92 shares or 16.73% in the most recent quarter. The Hedge Fund company now holds 458 shares of AMGN which is valued at $70,161. Amgen makes up approx 0.03% of Tortoise Investment Management’s portfolio.Btc Capital Management reduced its stake in AMGN by selling 2,829 shares or 29.45% in the most recent quarter. The Hedge Fund company now holds 6,778 shares of AMGN which is valued at $1 Million. Amgen makes up approx 0.24% of Btc Capital Management’s portfolio.

Amgen opened for trading at $148.92 and hit $151.71 on the upside on Friday, eventually ending the session at $150.18, with a gain of 1.02% or 1.51 points. The heightened volatility saw the trading volume jump to 30,76,109 shares. Company has a market cap of $112,817,769 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.